Thursday, 22 May 2025
Scientists have developed a method for analysing the structure of lipid nanoparticles that could be used to improve vaccine and drug delivery, targeting a wide range of health issues.
A team led by scientists at the University of Nottingham’s School of Pharmacy demonstrated a new cryogenic mass spectrometry approach for depth profiling frozen tiny lipid nanoparticles to reveal the layers and orientation of the constituent molecules. The findings have been published today in Nature’s Mass Spectrometry Method Development collection.
Lipid nanoparticles (LNP’s) came to prominence for delivery of RNA with the success of the Moderna and Pfizer BioNTech COVID-19 vaccines. They are also used to deliver therapeutic treatments including using small interfering RNA-based drugs to treat the rare hereditary disease of polyneuropathy (Alnylam Pharmaceuticals). Areas of development include lung-targeted gene therapy which is particularly challenging, but LPN’s have the potential to treat a range of diseases including cystic fibrosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma and more.
This research provides insight into the relative positions of each component within lipid nanoparticles. This knowledge can help clarify the intricate behaviour of LNPs and contribute to the design of formulations with unique bio-properties that are more efficient and safer. The research findings could also be used in the future to help quality control during the scale-up of manufacturing processes, enhancing the translation of LNPs from the laboratory to clinical applications.
The research team which also included Sail Biomedicines, Cambridge, MA, Massachusetts Institute of Technology, Cambridge, MA and the National Physical Laboratory, Teddington UK, utilised Cryogenic OrbitrapTM secondary ion microscopy (Cryo-OrbiSIMS) to provide structural details of the lipid nanoparticles. This high pressure freezing cryo-preparation facility keeps biological samples maintained close to their native state.
Characterising the native surface of delicate hydrated pharmaceutical systems used in the body has been a significant challenge for some time. This cryogenic molecular surface and interfacial analysis advance makes this exciting possibility real. We expect to apply this new method to many systems, including lipid nanoparticles, other pharmaceutical delivery systems and hydrated biomaterials.
Dr Robert Langer, from Massachusetts Institute of Technology is also an author on the research paper, he said: “Effective drug delivery relies on an intricate mix of molecules in lipid nanoparticles to effectively deliver RNA therapeutics, but these can vary in efficacy and can be difficult to engineer. This research provides a new way of characterising and understanding the make-up of lipid nanoparticles which could pave the way for engineering more potent and targeted LNPs to enable the broadest application of RNA therapies for all types of diseases.”
“At Sail Biomedicines, we are proud to have contributed to advancing the understanding of lipid nanoparticle surface structures," said Kerry Benenato, Ph.D., Chief Platform Officer at Sail Biomedicines. "The surface of lipid nanoparticles plays a critical role in shaping their behavior in the human body. By enabling precise surface characterization, the technology the team has developed paves the way for the engineering by design of LNP-based medicines with tunable properties, including biodistribution, thereby expanding the potential of RNA-based therapeutics.”
Story credits
More information is available from Professor Morgan Alexander on Morgan.Alexander@nottingham.ac.uk
Notes to editors:
About the University of Nottingham
Ranked 97 in the world and 17th in the UK by the QS World University Rankings, the University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the third most targeted by the UK's top employers, according to The Graduate Market in 2024 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.
More news…